Pemetrexed Injection, Solution, Concentrate
Product Images NDC 0409-1045

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 0409-1045). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Pemetrexed 01)

Chemical structure diagram of the active ingredient Pemetrexed, showing its molecular structure with atoms and bonds, including sodium carboxylate groups and hydration (2.5 H2O).*

FDA Label Image

Figure 1 (Pemetrexed 02)

A survival probability curve comparing Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC) over a 30-month period. The chart shows survival time in months on the x-axis and survival probability on the y-axis, including a table of patients at risk at various time points for each treatment group.*

FDA Label Image

Figure 2 (Pemetrexed 03)

A survival probability Kaplan-Meier curve chart comparing survival time (months) for patients treated with Pemetrexed + Cisplatin (solid line) versus Gemcitabine + Cisplatin (dotted line). The x-axis shows survival time in months up to 30, while the y-axis shows survival probability from 0 to 1. The chart includes a table of patients at risk at different time points for both treatment groups.*

FDA Label Image

Figure 3 (Pemetrexed 04)

A Kaplan-Meier survival curve comparing survival probability over time in months for two treatment groups: Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC). The x-axis shows survival time up to 30 months, and the y-axis shows survival probability from 0 to 1. Below the graph, a table indicates the number of patients at risk in each group over time.*

FDA Label Image

Figure 4 (Pemetrexed 05)

A Kaplan-Meier survival probability curve comparing Pemetrexed injection versus placebo over time in months. The y-axis represents survival probability, and the x-axis shows survival time in months up to 42. The graph includes patient numbers at risk at various time points for both Pemetrexed and placebo groups.*

FDA Label Image

Figure 5 (Pemetrexed 06)

A survival curve chart showing survival probability over time (months) comparing Pemetrexed versus Placebo. The chart includes two lines representing each group, with survival probability on the y-axis and survival time in months on the x-axis. A table below indicates the number of patients at risk at various time points for both groups.*

FDA Label Image

Figure 6 (Pemetrexed 07)

A survival probability graph comparing Pemetrexed and Placebo over time up to 42 months. The y-axis shows survival probability from 0 to 1, and the x-axis shows survival time in months. The graph includes lines for Pemetrexed and Placebo groups and a table listing patients at risk at various time points for each group.*

FDA Label Image

Figure 7 (Pemetrexed 08)

A survival curve chart comparing the survival probability over time in months between Pemetrexed and placebo groups. The chart includes a line for Pemetrexed with higher survival probabilities and a dotted line for placebo with lower probabilities. Below the x-axis, a table shows the number of patients at risk for each group at various time points.*

FDA Label Image

Figure 8 (Pemetrexed 09)

A survival probability line graph comparing Pemetrexed plus Cisplatin (solid line) and Cisplatin alone (dotted line) over a 30-month period. The x-axis represents survival time in months, and the y-axis shows survival probability. Patient risk numbers for each group are displayed below the graph at multiple time points.*

FDA Label Image

Logo (Pemetrexed 10)

FDA Label Image

Logo (Pemetrexed 11)

FDA Label Image

Principal Display Panel (4 mL Vial Label)

Label for Pemetrexed Injection 100 mg/4 mL (25 mg/mL) concentrate for intravenous infusion, single dose vial, by Hospira, Inc. The label notes storage between 2°C to 8°C, a warning that it is a hazardous drug, and includes prescribing information references, as well as a barcode and lot/expiration placeholders.*

FDA Label Image

Principal Display Panel (4 mL Vial Carton)

Pemetrexed Injection 100 mg/4 mL (25 mg/mL) single-dose vial carton label. The label includes dosing dilution instructions, storage conditions requiring refrigeration at 2°C to 8°C (36°F to 46°F), and warnings about hazardous drug status. Manufactured by Zydus Hospira Oncology Private Ltd., India, and distributed by Hospira, Inc., Lake Forest, IL, USA.*

FDA Label Image

Principal Display Panel (20 mL Vial Label)

Label for Pemetrexed Injection 500 mg/20 mL solution concentrate for intravenous infusion by Hospira, Inc. Features dosing information, storage instructions between 2°C to 8°C, warning of hazardous drug status, and NDC 0409-2188-01. Includes barcode and spaces for lot and expiration dates.*

FDA Label Image

Principal Display Panel (20 mL Vial Carton)

Pemetrexed Injection 500 mg/20 mL (25 mg/mL) concentrate for intravenous infusion, single-dose vial packaging label. Manufactured by Hospira, Inc., the label includes storage instructions to refrigerate at 2°C to 8°C (36°F to 46°F) and warns that the drug is hazardous. The label also provides dilution instructions and emphasizes discarding unused portions.*

FDA Label Image

Principal Display Panel (40 mL Vial Label)

Label for Pemetrexed Injection 1 g/40 mL (25 mg/mL) concentrate for intravenous infusion by Hospira, Inc. The label indicates storage instructions at 2°C to 8°C, and includes warnings, dosage form, NDC 0409-3532-01, barcode, and dilution guidance.*

FDA Label Image

Principal Display Panel (40 mL Vial Carton)

Pemetrexed Injection 1 g/40 mL (25 mg/mL) intravenous infusion single-dose vial carton. The label includes dilution instructions, storage requirements at 2°C to 8°C (36°F to 46°F), and warnings that the drug is hazardous. Manufactured by Zydus Hospira Oncology Private Ltd. and distributed by Hospira, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.